Active, not recruitingPhase 2NCT04947319
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Studying Primary central nervous system lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ono Pharmaceutical Co. Ltd
- Principal Investigator
- Project LeaderOno Pharmaceutical Co. Ltd
- Intervention
- Tirabrutinib(drug)
- Enrollment
- 119 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
- Mayo Clinic- Phoenix, Phoenix, Arizona, United States
- City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States
- University of California, Irvine, Irvine, California, United States
- Stanford University, Palo Alto, California, United States
- University of Colorado Denver, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University, Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
- Mayo Clinic- Jacksonville, Jacksonville, Florida, United States
- University of Miami-Sylvester Cancer Center, Miami, Florida, United States
- Orlando Health, Orlando, Florida, United States
- Moffitt Cancer Center- Miami, Pembroke Pines, Florida, United States
- Piedmont Healthcare, Atlanta, Georgia, United States
- University of Kentucky, Lexington, Kentucky, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04947319 on ClinicalTrials.govOther trials for Primary central nervous system lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd
- RECRUITINGPHASE2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPHASE2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho
- RECRUITINGPHASE2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation
- RECRUITINGPHASE1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center
See all trials for Primary central nervous system lymphoma →